Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew A. Lunning, Julie M. Vose, Loretta J. Nastoupil, et al.
Blood (2019) Vol. 134, Iss. 21, pp. 1811-1820
Open Access | Times Cited: 81

Showing 26-50 of 81 citing articles:

The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment
Claudia Pérez‐Carretero, Isabel González-Gascón-y-Marín, Ana E. Rodríguez‐Vicente, et al.
Diagnostics (2021) Vol. 11, Iss. 5, pp. 853-853
Open Access | Times Cited: 21
Management of Drug Resistance in Mantle Cell Lymphoma
Gaël Roué, Brigitte Sola
Cancers (2020) Vol. 12, Iss. 6, pp. 1565-1565
Open Access | Times Cited: 22
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
Walter Hanel, Narendranath Epperla
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 20
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, et al.
Blood Advances (2021) Vol. 5, Iss. 23, pp. 5332-5343
Open Access | Times Cited: 19
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Oluwatobi Odetola, Shuo Ma
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 5, pp. 130-143
Open Access | Times Cited: 7
The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma
Epameinondas Koumpis, Vasileios Georgoulis, Konstantina Papathanasiou, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2658-2658
Open Access | Times Cited: 2
Duvelisib for the treatment of chronic lymphocytic leukemia
Anna Maria Frustaci, Alessandra Tedeschi, Marina Deodato, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 11, pp. 1299-1309
Closed Access | Times Cited: 20
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma
Paul Harker‐Murray, Lauren Pommert, Matthew J. Barth
Journal of the National Comprehensive Cancer Network (2020) Vol. 18, Iss. 8, pp. 1125-1134
Closed Access | Times Cited: 17
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
Paul J. Hampel, Kari G. Rabe, Timothy G. Call, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 9
Open Access | Times Cited: 10
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Robert Pytlík, Kamila Polgárová, Jana Karolová, et al.
Vaccines (2020) Vol. 8, Iss. 4, pp. 708-708
Open Access | Times Cited: 15
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Alexey V. Danilov, Massimo Magagnoli, Matthew J. Matasar
The Oncologist (2022) Vol. 27, Iss. 1, pp. 57-66
Open Access | Times Cited: 9
Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer
Chengbin Yang, Yimin Gong, Yunjian Gao, et al.
Bioorganic & Medicinal Chemistry Letters (2023) Vol. 82, pp. 129152-129152
Closed Access | Times Cited: 5
Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models
Manojkumar R. Shukla, Sukanya Patra, Mahip Verma, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 23, pp. 14700-14723
Closed Access | Times Cited: 13
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?
Mariana Tannoury, Delphine Garnier, Santos A. Susín, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6026-6026
Open Access | Times Cited: 8
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Shinichi Makita, Rika Hosoba, Kensei Tobinai
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 9, pp. 1105-1120
Closed Access | Times Cited: 12
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana C. Santos, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
Carol Moreno
Hematology (2020) Vol. 2020, Iss. 1, pp. 33-40
Open Access | Times Cited: 11
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia
Benjamin L. Lampson, Jennifer R. Brown
Hematology/Oncology Clinics of North America (2021) Vol. 35, Iss. 4, pp. 807-826
Open Access | Times Cited: 9
The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis
Alice Barros Câmara, Igor Augusto Brandão
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 1, pp. 93-120
Closed Access | Times Cited: 3
Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials
Elżbieta Iskierka‐Jażdżewska, Tadeusz Robak
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 7, pp. 709-722
Closed Access | Times Cited: 8
Management of relapsed follicular lymphoma
Thomas D. Rodgers, Paul M. Barr
Annals of Lymphoma (2021) Vol. 5, pp. 14-14
Open Access | Times Cited: 7
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia
Thomas J. Kipps
The Cancer Journal (2021) Vol. 27, Iss. 4, pp. 306-313
Closed Access | Times Cited: 7
Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
Patrick Willard, John McKay, Victor Yazbeck
Leukemia Research Reports (2021) Vol. 16, pp. 100275-100275
Open Access | Times Cited: 7
The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia
Iwona Hus, Aleksander Salomon‐Perzyński, Tadeusz Robak
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 7, pp. 799-812
Closed Access | Times Cited: 6
Chronic lymphocytic leukaemia Australasian consensus practice statement
Mary Ann Anderson, Rory Bennett, Xavier C. Badoux, et al.
Internal Medicine Journal (2023) Vol. 53, Iss. 9, pp. 1678-1691
Open Access | Times Cited: 2

Scroll to top